Holen Sie sich die Stockscreener-App
0.6217
0.60%
0.0037
Schlusskurs vom Vortag:
$0.618
Offen:
$0.64
24-Stunden-Volumen:
323.12K
Relative Volume:
0.54
Marktkapitalisierung:
$149.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$1.24B
KGV:
0.0244
EPS:
25.475
Netto-Cashflow:
$-31.80M
1W Leistung:
-13.53%
1M Leistung:
-10.84%
6M Leistung:
-25.24%
1J Leistung:
-40.51%
1-Tages-Spanne:
$0.6106
$0.6465
1-Wochen-Bereich:
$0.6106
$0.735
52-Wochen-Spanne:
$0.6106
$2.10
Enlivex Ltd Stock (ENLV) Company Profile
Compare ENLV vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENLV
Enlivex Ltd
|
0.6217 | 149.86M | 0 | 1.24B | -31.80M | 25.48 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enlivex Ltd Stock (ENLV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-02 | Bestätigt | H.C. Wainwright | Buy |
Enlivex Ltd Aktie (ENLV) Neueste Nachrichten
Enlivex Therapeutics Ltd (ENLV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enlivex Therapeutics Ltd (ENLV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enlivex Therapeutics Ltd (ENLV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enlivex Therapeutics Ltd (ENLV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Enlivex Therapeutics Ltd (ENLV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enlivex Therapeutics Ltd (ENLV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Enlivex Therapeutics Ltd (ENLV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ENLV Q4 2025 Earnings: Massive EPS Miss Highlights Challenging QuarterProfit Announcement - newsline.com
Enlivex Secures Australian Patent for Allocetra in Osteoarthritis Treatment - GuruFocus
Enlivex (ENLV) Slips Slightly as Stock Tests Key Support Near $0.63Positive Gamma - newsline.com
Enlivex receives Australian patent for osteoarthritis treatment - Investing.com
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis - The Manila Times
Enlivex (ENLV) Shares Slide Over 6% as Stock Tests Key Support at $0.64Last Point Support - newsline.com
ENLV Q4 2025 Earnings: Deep Losses and Clinical Progress Amid Severe EPS MissEarnings Revision Upgrade - newsline.com
Enlivex Therapeutics stock (IL0011283620): Data monitoring, Nasdaq notice and next steps for investo - AD HOC NEWS
ENLV Q4 2025 Earnings: Significant EPS Miss Reflects Clinical-Stage DevelopmentHigh Estimate Range - newsline.com
Number of shareholders of Enlivex Ltd. – LSX:A119KH - TradingView
RAIN Highlights $200M Ecosystem Commitment, $100M Liquidity Expansion, and World Cup Growth Strategy Ahead of Version 2 Launch - GlobeNewswire Inc.
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026 - marketscreener.com
Enlivex brings longevity‑prediction markets pitch to $18T Paris summit - Stock Titan
Enlivex to present knee osteoarthritis trial data at EULAR By Investing.com - Investing.com South Africa
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026 - The Manila Times
Enlivex to present knee osteoarthritis trial data at EULAR - Investing.com
Experimental cell therapy eases knee arthritis pain for 6 months - Stock Titan
Enlivex Values RAIN Token Treasury at $1.16 Billion as Rain Protocol Climbs to No. 3 in Prediction Markets - The Globe and Mail
Enlivex (ENLV) Tests Key Support at $0.72 as Downtrend IntensifiesImbalance Zone - The Legal Advocate
Enlivex's RAIN tokens valued at $1.16B as Rain protocol ranks 3rd in global prediction markets. - Pluang
Enlivex reports $1.16 billion in RAIN token holdings - Investing.com UK
Enlivex reports $1.16 billion in RAIN token holdings By Investing.com - Investing.com India
Enlivex Highlights $100M Liquidity Boost for Rain as Treasury-Backed Prediction Market Enters Global Top Three - The Globe and Mail
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board - The Manila Times
RAIN treasury hits $1.16B as Enlivex (Nasdaq: ENLV) details prediction markets push - Stock Titan
Enlivex Ltd. (ENLV) Rallies 14%: Key Levels and Technical OutlookBPI Reversal - The Legal Advocate
Enlivex Highlights Rain Foundation's $100M Commitment - GuruFocus
Enlivex (NASDAQ: ENLV) details $100M Rain liquidity and massive RAIN token holdings - Stock Titan
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity - marketscreener.com
$100M liquidity push lifts Rain into top 3 prediction markets - Stock Titan
Enlivex Surges 12.87% as Biotech Stock Breaks Above Key Support LevelsCTA Positioning - newsline.com
Enlivex (ENLV) Shares Slide 4.67% as Stock Tests Key Support at $0.65Ichimoku Entry - Newser
ENLV Q4 2025 Earnings: Significant EPS Miss Amid Development Stage CostsROE Trend Analysis - The Legal Advocate
Enlivex Ltd. (ENLV) Slides Slightly as Shares Hover Near Key Support LevelFast Moving Stocks - thelegaladvocate.com
Enlivex Ltd expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Enlivex (ENLV) Edges Higher After Testing Key Support at $0.69Ichimoku TK Cross - Newser
ENLV Q1'26 Earnings: EPS estimate is (0.02) USD - TradingView
Enlivex Therapeutics Initiates Phase 2b Trial in US, Doses First Patient with Allocetra for Knee Osteoarthritis - geneonline.com
Enlivex Doses First US Patient in Phase 2b Knee Osteoarthritis Trial - Moomoo
Enlivex (ENLV) Begins Phase 2b Clinical Trial for Osteoarthritis Treatment - GuruFocus
Enlivex doses first U.S. patient in knee osteoarthritis trial - Investing.com UK
Finanzdaten der Enlivex Ltd-Aktie (ENLV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):